On March 20, 2025, the U.S. Food and Drug Administration (FDA) approved a supplemental application for Tremfya (guselkumab). The application, BLA 761061 S-24, was sponsored by Janssen Biotech and specifically pertained to the drug's efficacy.
Background
Guselkumab, known by its brand name Tremfya, is a therapeutic agent developed by Janssen Biotech. This supplemental approval relates to an update or expansion of information concerning the drug's established efficacy profile.
What this means
The FDA's approval of this supplemental application for Tremfya (guselkumab) signifies a regulatory update regarding its efficacy. Such approvals can indicate expanded data supporting existing indications, refinements in dosing, or other label enhancements that reinforce how well the drug works for its approved uses.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 761061 S-24 was posted on March 20, 2025, on accessdata.fda.gov.